← back to the index
DV-003 orthopedic implant 2010

The DePuy ASR Hip — Metal Poisoning, a 2010 Recall, and $4 Billion

implant-failuremetal-toxicity-metallosisrevision-surgeryorthopedic-surgery2000s2010s
Patients implanted
~93,000 worldwide (since 2003)
Failure or harm
5-yr revision ~12-13% at recall, rising toward ~40% at ~6 yrs (vs ~5% expected); cobalt-chromium metallosis
In use
~7 yrs (2003 launch – 24 Aug 2010 recall)
Status
Recalled (Class I)

Summary

When DePuy Orthopaedics, the joint-replacement arm of Johnson & Johnson, recalled its Articular Surface Replacement (ASR) hip systems worldwide on 24 August 2010, the gap between the device's promise and its harm was already legible in national arthroplasty registries: the ASR had been sold as a durable, large-diameter metal-on-metal joint suited to younger, more active patients, yet by the time of recall the company itself conceded a five-year revision rate near 13 percent — roughly one in eight — against an expected figure on the order of 5 percent, and independent registry follow-up would push the early-failure rate toward 40 percent within six years. Roughly 93,000 patients across the world had received one.

The mechanism was metallurgical, not surgical. The ASR paired a cobalt-chromium ball against a cobalt-chromium cup; in motion the two surfaces shed microscopic metal debris and released cobalt and chromium ions into surrounding tissue and the bloodstream. The local result was metallosis and adverse reaction to metal debris — soft-tissue necrosis, fluid-filled pseudotumors, and bone destruction that frequently demanded a second, more difficult operation. The systemic burden of circulating cobalt was linked in the literature to cardiac, neurological, and thyroid effects. The very design choice marketed as an advantage — a large bearing for stability — increased the surface area generating that debris, particularly when the shallow cup was implanted at a steep angle.

DePuy did not act on the first signal. The Australian Orthopaedic Association National Joint Replacement Registry identified an elevated revision rate for the ASR resurfacing system in 2007 and for the ASR XL acetabular system the following year, and conveyed the finding to the company in a series of reports. DePuy withdrew the ASR from Australia in 2009 citing "commercial reasons," then continued selling it elsewhere until the 2010 global recall. In the United States, the ASR XL had reached market in 2008 through the FDA's 510(k) clearance route — which permits sale on the basis of similarity to existing devices rather than fresh clinical proof of safety — while the resurfacing version was never approved for U.S. use at all. Litigation, not pre-market review, fixed the bill: J&J's November 2013 U.S. settlement framework began at roughly $2.5 billion for about 8,000 revision claims and, with later expansions, grew past $4 billion as more than 11,000 plaintiffs came forward.

Timeline

2003
ASR enters the market
DePuy launches the ASR Hip Resurfacing System and the large-diameter ASR XL Acetabular System, marketed for younger, active patients on the promise of durability and range of motion.
2005–2008
Global uptake
Roughly 93,000 ASR units are implanted worldwide; the resurfacing version sells in the U.K., Australia, and Europe but not the United States.
2007
First registry alarm
The Australian National Joint Replacement Registry flags a significantly elevated revision rate for the ASR resurfacing system and notifies DePuy.
2008
510(k) clearance and a second alarm
The ASR XL acetabular system reaches the U.S. market via FDA 510(k) clearance; the Australian registry now flags the XL system's revision rate as well.
Aug 2009
FDA rejects the resurfacing PMA
The FDA informs DePuy that the safety and effectiveness data for the ASR resurfacing device are inadequate; DePuy withdraws the application and the U.S. resurfacing device is never approved.
Nov–Dec 2009
Quiet exit from Australia
DePuy withdraws the ASR from the Australian market citing "commercial reasons," not safety, while sales continue in other countries.
24 Aug 2010
Worldwide recall
DePuy recalls all ASR systems sold since 2003, conceding a ~13% five-year revision rate; the action is later treated as a Class I recall reflecting risk of serious injury.
Dec 2010
U.S. litigation consolidated
The Judicial Panel on Multidistrict Litigation centralizes federal ASR cases in the Northern District of Ohio before Judge David A. Katz.
2011–2012
Registry follow-up worsens
Australian and U.K. registry analyses report five-year revision rates of roughly 9–13% for the ASR, with later cohorts trending far higher — toward 40% at six years in some series.
Feb–Mar 2012
Regulators and journals weigh in
The BMJ and the U.K. MHRA publish on metal-on-metal wear, elevated cobalt-chromium ion levels, and adverse reaction to metal debris; the MHRA tightens metal-on-metal surveillance.
Nov 2013
The U.S. settlement
J&J agrees to a settlement framework beginning near $2.5 billion to resolve about 8,000 revision claims, with base awards reported around $250,000 per qualifying patient.
2014–2019
Settlement expands past $4 billion
Supplemental programs and additional claimants — more than 11,000 U.S. plaintiffs in total — push aggregate U.S. payouts beyond $4 billion.

A Bigger Bearing Sold as a Better Joint

The ASR's commercial logic was intuitive and wrong. Conventional hip replacements pair a metal or ceramic ball against a polyethylene cup; the plastic wears, but slowly, and its debris is biologically tolerable. Metal-on-metal promised to eliminate plastic wear and permit a larger femoral head, which resists dislocation and restores range of motion — an attractive pitch for younger, athletic patients facing decades on an implant. DePuy designed the ASR around an unusually large cobalt-chromium bearing and a shallow, monoblock cup, and marketed those features as advantages. The metallurgy undercut the premise. A larger bearing sweeps a larger contact area, and a shallow cup is unforgiving of surgical positioning: implanted at too steep an angle, the head rides the rim and concentrates contact stress, accelerating wear. The device that was supposed to outlast plastic instead generated a stream of metal particles, and the bigger ball that promised stability enlarged the surface doing it. The selling point was the defect.

The Registry That Saw It in 2007 and the Recall That Came in 2010

The harm did not hide. National joint registries — pooled, mandatory databases of every implant and every revision — exist precisely to catch a failing device before the failures accumulate, and the Australian registry did its job. By 2007 it had isolated a revision rate for the ASR resurfacing system well above comparable implants, and by 2008 the same for the ASR XL. Stephen Graves, who directed the registry, would later say the data had been conveyed to DePuy across multiple reports and that the company had reason to withdraw the device years before it did. DePuy's response was to leave the Australian market in 2009 for "commercial reasons" — a phrasing that disclosed nothing about safety — while continuing to sell the ASR elsewhere. The five-year revision figures the company ultimately conceded at recall, around 12 to 13 percent, were already several times the expected rate, and later registry cohorts were worse, with some series reporting failure approaching 40 percent at six years. The signal was external, quantified, and early. What failed was not detection but response.

Settlement as the Only Binding Verdict

No clinical trial gatekeeper ever blocked the ASR in the United States, because none was required. The ASR XL acetabular system reached American patients in 2008 through the 510(k) pathway, which clears a device by asserting "substantial equivalence" to one already on the market rather than demanding new evidence of safety — a route critics had long flagged as a gap for high-risk implants. The resurfacing version fared differently only because DePuy's premarket-approval application was rejected as inadequate in 2009, so it was never U.S.-approved. After the 2010 recall, the reckoning ran through the courts. Federal cases were consolidated before Judge David A. Katz in Ohio, and in November 2013 J&J agreed to a settlement framework opening near $2.5 billion to compensate roughly 8,000 patients who had undergone revision, with base awards reported around $250,000. As supplemental tracks opened and the claimant count climbed past 11,000, aggregate U.S. liability grew beyond $4 billion. The device had been off the market for three years before the first settlement number was fixed; the revisions and the registries, not any regulator, wrote the price.

Contributing Factors

01
A design whose selling point was its failure mechanism
The large cobalt-chromium bearing marketed for stability and range of motion was the same feature that maximized metal-wear surface area, and the shallow monoblock cup was intolerant of imperfect positioning. The advertised advantage and the harm mechanism were one object, so the marketing claim and the defect could not be separated.
02
Registry signals received and not acted upon
The Australian joint registry identified elevated ASR revision rates in 2007–2008 and reported them to DePuy, which withdrew from that market in 2009 citing "commercial reasons" while selling on elsewhere. The early-warning system worked; the failure was the manufacturer's decision to treat a quantified safety signal as a regional commercial matter.
03
Clearance without proof under 510(k)
The ASR XL reached U.S. patients in 2008 by asserting equivalence to predicate devices rather than demonstrating safety in trials. A high-risk permanent implant entered the body of tens of thousands of Americans through a route designed for low-risk equivalence — a structural gap the product exploited and later helped expose.
04
Withdrawal staged as commerce, not safety
Leaving Australia in 2009 for "commercial reasons" let DePuy exit a market where the data looked worst without triggering a safety recall or alerting patients elsewhere. Framing a safety-driven retreat as a business decision delayed the global recall by roughly a year and kept the device in active distribution.
05
Settlement as the terminal regulator
With no pre-market trial having stopped the ASR, U.S. multidistrict litigation became the only binding adjudicator, converting open-ended revision liability into a settlement framework that began near $2.5 billion and grew past $4 billion. The mass-tort settlement, not any agency order, set the final accounting.

Aftermath

The ASR's most durable consequence was the collapse of the metal-on-metal hip as a category. Surgeons and registries that had embraced large-diameter all-metal bearings abandoned them; regulators including the U.K. MHRA and the U.S. FDA tightened surveillance, mandated ion-level monitoring for patients still carrying such implants, and effectively ended routine metal-on-metal use. The financial reckoning ran through J&J's U.S. settlement framework, which opened near $2.5 billion for about 8,000 revision claims in November 2013 and expanded past $4 billion as the claimant count exceeded 11,000; comparable schemes followed in other countries, and in India the government moved to compensate roughly 4,700 affected patients. The episode also became a standing case against the 510(k) clearance route for high-risk implants and a standing argument for the value of mandatory joint registries — the very instruments that had caught the device years before its maker recalled it. Today the DePuy ASR is the orthopedic byword for a device its own market data had condemned long before withdrawal: the implant the registries flagged in 2007 and the company recalled in 2010.

Lessons

  1. Treat a national registry signal as a recall trigger, not a regional commercial input — when an independent dataset shows your implant failing several times above the expected rate, the obligation is global retrieval, not a quiet market exit.
  2. Distrust any design whose marketed advantage is inseparable from its wear mechanism; a larger bearing that improves stability by enlarging the metal contact area has built its selling point and its defect from the same surface.
  3. Read regulatory clearance by equivalence as the absence of proof, not the presence of safety — a 510(k) path for a permanent high-risk implant is a gap to close, not a license to skip clinical evidence.
  4. Name a withdrawal for what drives it: labeling a safety retreat a "commercial" decision misleads patients and surgeons in every market you keep selling to, and discovery will later read the euphemism as concealment.
  5. Build and heed the early-warning instrument before you need it — the value of a mandatory registry is realized only if the manufacturer acts on the year-one signal rather than the year-seven settlement.

References